Mesoblast Ltd
ASX:MSB
Mesoblast Ltd
Cash from Operating Activities
Mesoblast Ltd
Cash from Operating Activities Peer Comparison
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Mesoblast Ltd
ASX:MSB
|
Cash from Operating Activities
-$59.1m
|
CAGR 3-Years
16%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
Immutep Ltd
ASX:IMM
|
Cash from Operating Activities
-AU$35.4m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
-10%
|
|
CSL Ltd
ASX:CSL
|
Cash from Operating Activities
$2.7B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
9%
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Cash from Operating Activities
AU$42.3m
|
CAGR 3-Years
31%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Cash from Operating Activities
AU$23.9m
|
CAGR 3-Years
130%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Cash from Operating Activities
-AU$19.4m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
-22%
|
See Also
What is Mesoblast Ltd's Cash from Operating Activities?
Cash from Operating Activities
-59.1m
USD
Based on the financial report for Dec 31, 2023, Mesoblast Ltd's Cash from Operating Activities amounts to -59.1m USD.
What is Mesoblast Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-1%
Over the last year, the Cash from Operating Activities growth was 2%. The average annual Cash from Operating Activities growth rates for Mesoblast Ltd have been 16% over the past three years , -1% over the past five years .